- Home
- BXC vs BCYC Comparison
BXC vs BCYC Comparison
Compare BXC & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BXC | BCYC |
|---|---|---|
| Founded | 2004 | 2009 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Wholesale Distributors | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 443.9M | 438.4M |
| IPO Year | 2004 | 2019 |
Fundamental Metrics
Financial Performance| Metric | BXC | BCYC |
|---|---|---|
| Price | $59.93 | $7.10 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 11 |
| Target Price | ★ $88.67 | $18.73 |
| AVG Volume (30 Days) | 103.7K | ★ 320.6K |
| Earning Date | 11-04-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.71 | N/A |
| Revenue | ★ $2,948,840,000.00 | $28,339,000.00 |
| Revenue This Year | $1.54 | N/A |
| Revenue Next Year | $4.30 | N/A |
| P/E Ratio | $35.12 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $52.71 | $6.03 |
| 52 Week High | $130.06 | $21.50 |
Technical Indicators
Market Signals| Indicator | BXC | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 46.43 | 50.66 |
| Support Level | $59.45 | $6.76 |
| Resistance Level | $65.99 | $7.83 |
| Average True Range (ATR) | 3.21 | 0.42 |
| MACD | 0.96 | 0.10 |
| Stochastic Oscillator | 56.93 | 58.06 |
Price Performance
Historical ComparisonAbout BXC Bluelinx Holdings Inc.
BlueLinx Holdings Inc is engaged in the wholesale distribution of residential and commercial building products. Its business products are split into two categories: Structural products include items such as lumber, plywood, oriented strand board, rebar, and remesh and Specialty products include items such as engineered wood, siding, millwork, outdoor living, specialty lumber and panels, and industrial products. The company's operations are carried out throughout the United States.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.